

**Supplementary figure 1:** Intracranial progression-free survival of patients that received Trastuzumab-Deruxtecan stratified after treatment indication (HER2+ green vs. HER2 low violet). The median icPFS of the HER2+ patients was 12.7 months (95% CI: 7.7 – 27.4 months), while that of the HER2 low patients was 7.5 months (95% CI: 2.8 – 12.5 months).

**Supplementary Table 1: Adverse events in patients treated with Sacituzumab-Govitecan and Trastuzumab-Deruxtecan**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Adverse events** | **SG** | **percentage** | **T-DXd** | **percentage** |
| Neutropenia all grades | 5 | 42 | 7 | 44 |
| ≥ 3° | 4 | 33 | 1 | 6 |
| Anemia all grades | 4 | 33 | 6 | 38 |
| ≥ 3° | 1 | 8 | 1 | 6 |
| Thrombocytopenia all grades | 1 | 8 | 4 | 25 |
| ≥ 3° | 0 | 0 | 1 | 6 |
| Pneumonitis all grades | 1 | 8 | 3 | 19 |
| ≥ 3° | 0 | 0 | 1 | 6 |
| Ejection fraction decrease all grades | 0 | 0 | 0 | 0 |
| ≥ 3° | 0 | 0 | 0 | 0 |
| **Dose reduction during treatment** | 4 | 33 | 2 | 13 |